Novartis AG (ADR) (NYSE:NVS)’ Afinitor was granted FDA orphan designation as a treatment of diffuse large B-cell lymphoma, according to a post to the regulator’s website. Novartis AG (ADR) (NYSE:NVS) net profit margin is 16.50% and weekly performance is -1.17%. On last trading day company shares ended up $89.01. Analysts mean target price for the company is $89.78. Novartis AG (ADR) (NYSE:NVS) distance from 50-day simple moving average (SMA50) is 2.84%.
On June 2, 2014, Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) shares advanced 0.93% in last trading session and ended the day on $21.75. AUXL Gross Margin is 72.80% and its return on assets is -6.40%. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) quarterly performance is -27.84%.
On June 2, 2014, Orexigen Therapeutics, Inc. (NASDAQ:OREX) announced that the United States Food and Drug Administration (FDA) has informed the Company that the FDA intends to reassign the Prescription Drug User Fee Act (PDUFA) action date for the NB32 New Drug Application to June 11, 2014, one day beyond the original assignment. The FDA noted that due to an inadvertent administrative error, the Agency had miscalculated the originally assigned PDUFA date. Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares moved up 1.40% in last trading session and was closed at $6.51, while trading in range of $6.27 – $6.61. Orexigen Therapeutics, Inc. (NASDAQ:OREX) year to date (YTD) performance is 15.63%.
Athersys, Inc. (NASDAQ:ATHX) reports Q1 adjusted EPS (9c), consensus (10c). Reports Q1 revenue $707,000, consensus $660,000. Athersys, Inc. (NASDAQ:ATHX) ended the last trading day at $1.62. Company weekly volatility is calculated as 6.50% and price to cash ratio as 2.77. Athersys, Inc. (NASDAQ:ATHX) showed a negative weekly performance of -8.99%.
On June 4, 2014, Cardinal Health Inc (NYSE:CAH) launched a new solution to make it easier and more time-efficient for retail pharmacies to help patients better understand and adhere to their medications. Cardinal Health Inc (NYSE:CAH) shares moved up 0.07% in last trading session and was closed at $70.77, while trading in range of $70.56 – $71.16. Cardinal Health Inc (NYSE:CAH) year to date (YTD) performance is 6.39%.